MedPath

A prospective surveillance for chemotherapy-induced nausea and vomiting

Not Applicable
Conditions
malignant tumor
Registration Number
JPRN-UMIN000006456
Lead Sponsor
Department of Pharmaceutical Services, Hiroshima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
900
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patient has any illness (e.g. central nervous system tumors, gastrointestinal obstruction, active peptic ulcer, brain metastasis) caused nausea or vomiting except for chemotherapy-induced nausea and vomiting 2) Patient is judged that it is unsuitable as a study patient by investigator (e.g. patient cannot complete study diary)

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete Response (no emesis and no rescue therapy) in overall phase (1 to 7 days)
Secondary Outcome Measures
NameTimeMethod
1) Complete Response in acute (day 1) and delayed (2 to 7 days) phase 2) Control rate of nausea/vomiting 3) dietary intake 4) Incidence of constipation 5) Degree of satisfaction to treatment of nausea and vomiting
© Copyright 2025. All Rights Reserved by MedPath